文献速递特殊人群用药

肝功能不全对维拉匹生药代动力学的影响:开放标签、单剂量、平行组研究

Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study.
PubMed 文献 · Br J Clin Pharmacol · 2019-07-10

本研究为1期开放标签、非随机、平行组药代动力学研究,评估选择性孕激素受体调节剂维拉匹生在轻度或中度肝功能不全(Child-Pugh A或B级)受试者中的药代动力学、安全性和耐受性。结果显示,轻度肝功能不全者游离维拉匹生暴露较对照高1.44倍(90%CI 0.91-2.26),中度者高1.74倍(90%CI 1.09-2.78);维拉匹生2 mg耐受良好,治疗中出现的不良事件发生率在各队列间相似。结论认为轻中度肝功能不全仅见暴露轻度增加(<1.75倍),未发现安全性问题,数据不支持轻中度肝功能不全患者需调整剂量。

要点

  • 轻中度肝功能不全者游离维拉匹生暴露分别较对照高1.44倍和1.74倍。
  • 维拉匹生2 mg单次给药耐受良好,各队列不良事件发生率相似。
  • 数据不支持轻中度肝功能不全患者需调整维拉匹生剂量。

核心结论

  • 轻中度肝功能不全患者维拉匹生暴露仅轻度增加(<1.75倍),未发现安全性问题,不支持剂量调整。

研究设计与样本

  • 受试者单次口服维拉匹生2 mg,评估药代动力学参数、参数关系及安全性结局。

主要发现

  • 维拉匹生达峰时间在给药后1-2小时。
  • 轻度肝功能不全者游离维拉匹生暴露为对照的1.44倍(90%CI 0.91-2.26)。
  • 中度肝功能不全者游离维拉匹生暴露为对照的1.74倍(90%CI 1.09-2.78)。
  • 肝功能不全者与匹配对照的最大观测游离峰浓度相似。
  • 维拉匹生2 mg耐受良好,治疗中出现的不良事件发生率在各队列间相似。

关键数值与推荐

  • 轻中度肝功能不全仅见暴露轻度增加<1.75倍,未发现安全性问题,不支持剂量调整。

临床怎么用

  • 轻中度肝功能不全患者使用维拉匹生2 mg单次给药无需调整剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: The study objective was to evaluate the pharmacokinetics of the selective progesterone receptor modulator vilaprisan in participants with hepatic impairment. Additionally, the safety and tolerability of vilaprisan were investigated. METHODS: In this phase 1, open-label, nonrandomised, parallel-group, pharmacokinetic study, men and women with mild or moderate hepatic impairment (Child-Pugh grade A or B) and control participants with normal hepatic function matched by age, weight and sex received a single oral 2 mg dose of vilaprisan. Key pharmacokinetic parameters, relationships between parameters and safety outcomes were measured. RESULTS: Thirty-six participants completed the study: 9 with mild hepatic impairment, 9 with moderate hepatic impairment and 18 matched control participants with normal hepatic function. Vilaprisan reached maximum plasma concentrations after 1-2 hours. Unbound vilaprisan exposure was 1.44-fold higher for participants with mild hepatic impairment vs controls (90% confidence interval: 0.91-2.26), and 1.74-fold higher for participants with moderate impairment vs controls (90% confidence interval: 1.09-2.78). The maximum observed unbound peak concentrations were similar for participants with hepatic impairment and matched controls. Vilaprisan 2 mg was well tolerated and the incidence of treatment-emergent adverse events was similar across cohorts. CONCLUSION: Only mild increases of <1.75-fold in exposure were observed in participants with mild or moderate hepatic impairment compared with control participants. No safety concern was identified. These data, alongside the excellent safety profile observed in phase 1 and 2 studies, do not indicate that a dose adjustment would be required in patients with mild or moderate hepatic impairment.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Chattopadhyay N, Riecke K, Ligges S, et al. Effect of hepatic impairment on the pharmacokinetics of vilaprisan: An open-label, single-dose, parallel-group study. Br J Clin Pharmacol. 2019. PMID: 31112623. doi:10.1111/bcp.13992

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。